Opportunities in the Next Generation Cancer Diagnostics Market include leveraging advancements in genomic and proteomic ...

The global HLA typing market is expected to expand at a compound annual growth rate (CAGR) of approximately 6% during the ...

Discover the latest advancements in pancreatic cancer treatment, including targeted therapies and next-generation sequencing, transforming patient care and outcomes.

This article is authored by Dr Amrit Kaur Kaler, consultant, molecular pathology, Kokilaben Dhirubhai Ambani Hospitals, ...

A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel ...

The use of next-generation sequencing (NGS) technologies to detect B-cell receptor (BCR) or T-cell receptor (TCR) clonotypes ...

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. | Quest ...

As next-generation sequencing (NGS) applications expand, researchers face growing pressure to generate accurate, uniform data from increasingly complex and low input samples.

Quest expects the new blood test will support response monitoring in clinical trials.

Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to ...

"By cleverly combining new techniques for analyzing DNA at the level of individual molecules, we can achieve real breakthroughs in research into conditions such as dementia," predicts Professor John ...